Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1273-1282

  Becker, Michael A ^a,e   Schumacher, H Ralph ^b   MacDonald, Patricia A ^d   Lloyd, Eric ^c   Lademacher, Christopher ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d Rheumatology/GI Therapeutic Area ^*

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Allopurinol; Febuxostat; Gout; Hyperuricemia; Serum urate

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URATE;

ARTHROPATHY; ARTICLE; B CELL LYMPHOMA; BENIGN TUMOR; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EAR DISEASE; ESOPHAGUS CANCER; FAMILIAL DISEASE; GASTRIC DYSMOTILITY; GASTROINTESTINAL DISEASE; GENETIC DISORDER; GOUT; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; INFESTATION; INNER EAR DISEASE; KIDNEY CANCER; KIDNEY DISEASE; LIVER FUNCTION TEST; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDIASTINUM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PANCREAS CANCER; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; STOMACH PARESIS; THORAX DISEASE; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY DYSFUNCTION; VASCULAR DISEASE;

ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HYPERURICEMIA; THIAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 67149083327     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080814     Document Type: Article

References (23)

1. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis 2007;65:215-221
2. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-1328
3. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324 (Pubitemid 44620440)
4. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-580
5. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-65 (Pubitemid 44309598)
6. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-325 (Pubitemid 38725128)
7. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-18 (Pubitemid 28236731)
8. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-360 (Pubitemid 34856121)
9. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-2416 (Pubitemid 39480701)
10. Allopurinol package insert. Apotex Corp., Weston, FL; 2006.
11. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007;20:391-395
12. Terkeltaub R. Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis 2006;64:82-86
13. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56. (Pubitemid 14216359)
14. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-1847 (Pubitemid 40215224)
15. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461 (Pubitemid 41781828)
16. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-1548
17. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12:22-34. (Pubitemid 40516043)
18. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
19. Schumacher HR Jr, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005;32:2368-2372 (Pubitemid 41780649)
20. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-549
21. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-934 (Pubitemid 43993484)
22. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a Preventive Cardiology Information System (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-630 (Pubitemid 351294901)
23. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-1650 (Pubitemid 44168841)